

2011/001

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

- / -

Industria y Comercio

SUPERINTENDENCIA

RECIBO DE CAJA

No. 11 - 003437

Bogotá D.C., 13 de 2011 - 17:00:38

RECIBIDO DE : BAKER & MCKENZIE

NI 900.034.906

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR. PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	353200315	12/01/2011	148.414.500.00

*** Conceptos Pagados ***

CANT.	RENTISTICO	CONCEPTO	Vr. UNDITARIO	Vr. CONCEPTO
1	50005-01-03 CAMBIO DE MODALIDAD Y MODIFICACIONES	EN CREACION CORRECCION A SOLICITUD EN TRAMITE / MODIFICA	118.000.00	118.000.00
				\$118.000.00

SON: **CIENTO DIECIOCHO MIL PESOS MONEDA CORRIENTE***

Responsable: _____

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 10-098657- -00003-0000

Fecha: 2011-02-14 17:12:34 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Evs: 378 FASENACIONALI
Act. 329 CTOINFORMACION Folios: 35


Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C. - Colombia

Web: www.sic.gov.co e-mail: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

Enero 13 de 2011 - 17:01:22

REIVINDICACIONES ENMENDADAS

1. Un compuesto de fórmula (I)



(I),

O una sal farmacéuticamente aceptable del mismo, caracterizado porque:

u y u' son independientemente 0, 1, 2, ó 3;

D y D' son cada uno independientemente seleccionados entre NR^5 , O, y S; en donde cada uno de R^5 es seleccionado independientemente entre hidrogeno, alcoxycarbonilo, alquilo, arilalcoxycarbonilo, carboxi, haloalquilo, hidroxí, (NR^aR^b) carbonilo, y trialquilosilialcoxialquilo;

cada R^1 y $\text{R}^{1'}$ son seleccionados independientemente entre alcoxi, alcoxialquilo, alcoxycarbonilo, alquilo, arilalcoxycarbonilo, carboxi, formilo, halo, haloalquilo, hidroxí, hidroxialquilo, $-\text{NR}^a\text{R}^b$ y (NR^aR^b) carbonilo;

R^2 es seleccionado entre hidrogeno, alcoxycarbonilo, alquilo, arilalcoxycarbonilo, carboxi,

haloalquilo, y (NR^aR^b) carbonilo; y


R^3 es seleccionado entre hidrogeno, alcoxi, alcoxialquilo, alcoxycarbonilo, alquilo, arilalcoxycarbonilo, carboxi, formilo, halo, haloalquilo, hidroxi, hidroxialquilo,
5 $-NR^aR^b$, (NR^aR^b) alquilo, y (NR^aR^b) carbonilo; ó

R^2 y R^3 , junto con los átomos de carbono a los que están enlazados forman un anillo aromático o no aromático opcionalmente de cinco a ocho miembros que contiene uno o dos heteroátomos seleccionados independientemente entre
10 nitrógeno, oxigeno y azufre; en donde el anillo de cinco a ocho miembros esta sustituido opcionalmente con uno, dos, o tres sustituyentes seleccionados independientemente de alcoxi, alcoxialquilo, alcoxycarbonilo, alquilo, alquilsulfonilo, arilo, arilalquilo, arilsulfonilo, carboxi,
15 formilo, halo, haloalcoxi, haloalquilo, hidroxi, hidroxialquilo, $-NR^aR^b$, (NR^aR^b) alquilo, (NR^aR^b) carbonilo, oxo, and espirociclo;

$R^{2'}$ y $R^{3'}$ junto con los átomos de carbono a los que están enlazados forman un anillo aromático o no aromático
20 opcionalmente de cinco a ocho miembros que contiene uno o dos heteroátomos seleccionados independientemente de nitrógeno, oxigeno y azufre; en donde el anillo de cinco a ocho miembros esta sustituido opcionalmente con uno, dos, o tres sustituyentes seleccionados independientemente de alcoxi,
25 alcoxialquilo, alcoxycarbonilo, alquilo, alquilsulfonilo,

arilo, arilalquilo, arilsulfonilo, carboxi, formilo, halo, haloalcoxi, haloalquilo, hidroxí, hidroxialquilo, $-NR^aR^b$, (NR^aR^b) alquilo, (NR^aR^b) carbonilo, oxo, and espirociclo;

R^4 y $R^{4'}$ son cada uno seleccionado
5 independientemente entre



10 en donde

cada uno de m es independientemente 0, 1, ó 2;

cada uno de s es independientemente 0, 1, 2, 3, ó
4;

cada uno de X es seleccionado independientemente
15 entre O, S, S(O), SO₂, CH₂, CHR⁶, y C(R⁶)₂; siempre que cuando
 n es 0, X se selecciona entre CH₂, CHR⁶, y C(R⁶)₂;

cada uno de R^6 es seleccionado independientemente
entre alcoxi, alquilo, arilo, halo, haloalquilo, hidroxí, y
 $-NR^aR^b$, en donde el alquilo puede opcionalmente formar un
20 anillo condensado de tres a seis miembros con un átomo de
carbono adyacente, en donde en el anillo de tres a seis
miembros está opcionalmente sustituido con uno o dos grupos
alquilo;

cada uno de R^7 se selecciona independientemente
25 entre hidrogeno y $R^{11}-C(O)-$ y $R^{11}-C(S)-$;

R^8 se selecciona entre hidrogeno y alquilo;

R^9 y R^{10} son cada uno seleccionado independientemente entre hidrogeno, alqueno, alcoxialquilo, alquilo, haloalquilo, y (NR^aR^b) alquilo; ó

5 R^9 y R^{10} , junto con el átomo de carbono al cual esta enlazado, forman un anillo de cinco a seis miembros opcionalmente saturado que contiene uno o dos heteroátomos seleccionados entre NR^z , O, y S; en donde R^z se selecciona entre hidrogeno y alquilo; y

10 cada uno de R^{11} se selecciona independientemente entre alcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilalquilo, arilo, arilalqueno, arilalcoxi, arilalquilo, ariloxialquilo, cicloalquilo, (cicloalquilo) alqueno, (cicloalquilo)alquilo, cicloalquiloxialquilo, haloalquilo, heterociclilo, heterociclilalqueno, heterociclilalcoxi, heterociclilalquilo, heterocicliloxialquilo, hidroxialquilo, $-NR^cR^d$, (NR^cR^d) alqueno, (NR^cR^d) alquilo, y (NR^cR^d) carbonilo.

20 2. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque D y D' son cada uno NR^5 .

3. Un compuesto de conformidad con la
25 reivindicación 2, o una sal farmacéuticamente aceptable del

mismo, caracterizado porque cada uno de R^5 se selecciona independientemente entre hidrogeno e hidroxil.

4. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque u y u' son cada uno 0.

5. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque R^2 se selecciona entre hidrogeno y haloalquilo.

10 6. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque R^3 se selecciona entre hidrogeno y halo.


15 7. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque R^2 y R^3 junto con los átomos de carbono a los cuales están enlazados, forman un anillo carbocíclico de seis o siete miembros.

20 8. Un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque $R^{2'}$ y $R^{3'}$, junto con los átomos de carbono a los que están enlazados, forman opcionalmente un anillo de seis a ocho miembros que opcionalmente contiene un heteroátomo seleccionado entre oxigeno, nitrógeno, y azufre;
25 en donde el anillo es sustituido opcionalmente con uno o dos

grupos alquilo.

9. Un compuesto de Formula (II)

5



(II),

10

o una sal farmacéuticamente aceptable del mismo, caracterizado porque

R² se selecciona entre hidrogeno y haloalquilo; y

R³ se selecciona entre hidrogeno y halo; o

15


R² y R³, junto con los átomos de carbono el cual esta enlazado, forma un anillo aromático o no aromático de cinco o seis miembros en el anillo carbociclico

20

R^{2'} y R^{3'} junto con los átomos de carbono a los que están enlazados, forman un anillo aromático o no aromático opcionalmente de seis a ocho miembros que contiene un heteroátomo seleccionado entre oxigeno, nitrógeno, y azufre; en donde el anillo es sustituido opcionalmente con uno o dos grupos alquilo;


R⁴ y R^{4'} son cada uno seleccionado independientemente entre

25




- 5 en donde
- cada uno de s es 0 ó 2;
- cada uno de R^6 se selecciona independientemente entre alquilo y halo, en donde alquilo forma un anillo condesado de tres miembros con un átomo de carbono adyacente;
- 10 cada uno de R^7 se selecciona independientemente entre hidrogeno y $R^{11}-C(O)-$;
- R^8 se selecciona entre hidrogeno y alquilo;
- R^9 y R^{10} son cada uno seleccionados independientemente entre hidrogeno y alquilo; y
- 15 cada uno de R^{11} se selecciona independientemente entre alquilo, arilalcoxi, arilalquilo y (NR^cR^d) alquilo.
10. Un compuesto caracterizado porque es selecciona entre:

20




25


5




10








15




20




25




5




10









15





20





25









5





10




15





20





25







5





10





15





20





25









5





10




15





20





25





5





10





15




20





25










5





10





15





20





25





5




10



15





20





25



5





10




15





20





25





5




10











15





20





25





5





10





15




20




25




5




10








15




20




25




5




10








15




20




25




5




10








15




20





25









5





10



15




20




25


5




10








15





20





25





5





10



15





20





25



5





10



15





20





25



5





10



15





20





25



5





10



15




20




25


5




10



15



20



25

;

y

o una sal farmacéuticamente aceptable del mismo.

11. Una composición caracterizada porque comprende un compuesto de conformidad con la reivindicación 1, o una
5 sal farmacéuticamente aceptable del mismo y un portador farmacéuticamente aceptable.

12. La composición de conformidad con la reivindicación 11, caracterizada porque además comprende uno o dos compuestos adicionales que tienen actividad anti-VHC.

10 13. La composición de conformidad con la reivindicación 12, caracterizada porque al menos uno de los compuestos adicionales es un interferón o una ribavirina.

14. La composición de conformidad con la reivindicación 13, caracterizada porque el interferón se
15 selecciona entre interferón alfa 2B, interferón alfa pegilado, interferón censisus, interferón alfa 2A e interferón tau linfoblastoide.

15. Un método para tratar una infección VHC en un paciente, caracterizado porque comprende administrar al
20 paciente una cantidad eficaz terapéuticamente de un compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo.

16. El método de conformidad con la reivindicación 15, caracterizado porque además comprende la administración
25 de uno o dos compuestos adicionales que tienen una actividad

anti-VHC antes, después o simultáneamente de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo.

17. El método de conformidad con la reivindicación 5 16, caracterizado porque al menos uno de los compuestos adicionales es un interferón o una ribavirina.

18. El método de conformidad con la reivindicación 17, caracterizado porque el interferón se selecciona entre interferón alfa 2B, interferón alfa pegilado, interferón 10 censensus, interferón alfa 2A e interferón tau linfoblastoide.

2020
Bogotá D.C.,

Doctor(a)
CORREA ORDOÑEZ ALVARO
Apoderado(a) y/o Representante de
BRISTOL-MYERS SQUIBB COMPANY

REFERENCIA	Radicación No.	10 98657
	Solicitud internacional	
	Fecha inicio fase nacional	
	Trámite	11
	Evento	378
	Actuación	416
	Oficio No.	12618
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase

Dado en Bogotá DC, 06 APR 2011



JOSE LUIS SALAZAR LOPEZ
Director de Nuevas Creaciones (C)

jfernand